Felicity Thomas

Contract manufacturing organizations need to adapt to successfully overcome the specific challenges posed by complex therapies.

To achieve further cost reductions in biosimilar manufacturing, a move away from traditional models is necessary.

A look at the Univercells' NevoLine bio manufacturing platform, which incorporates principles of automated and continuous bioprocessing.

Globally accepted products are becoming increasingly in demand, leading to more need for regulatory harmonization, particularly for biosimilars.

Technical advances in process understanding and control must be accompanied by a change in mindset.

As biologics continue to push boundaries, the industry needs to take a holistic approach to formulation to ensure success.

Optimizing the patient experience and technological advances can positively impact adherence.